ALS Clinical Trial
Official title:
Coping Effectiveness Training for Recently Diagnosed ALS Patients and Care Partners
The investigators propose to adapt and pilot test a behavioral intervention for recently
diagnosed patients with Amyotrophic Lateral Sclerosis (ALS), and/or a family care partner.
ALS fatal neurodegenerative disease, the diagnosis of which can have a devastating impact on
patients and their families. Our eight session intervention is derived from Coping
Effectiveness Training, a manualized intervention based on stress and coping theory. It is
designed to strengthen coping skills and alleviate distress following diagnosis.
Participants (patients and/or care partners) will be recruited from the Eleanor and Lou
Gehrig MDA/ALS Research Center, Columbia University. The main outcomes are changes in
distress level, depression and anxiety symptoms, and coping self-efficacy.
Once the investigators gain preliminary experience with the manual, get some sense of
feasibility and acceptance, and learn about patient and care partner reactions, the
investigators will be better able to prepare a grant application seeking NIH support for the
development of the intervention, with the eventual goal of a multisite randomized controlled
trial (RCT).
ALS is a rare, devastating, fatal neurodegenerative disease of largely unknown cause.
Average survival after diagnosis is about 3 years. The diagnostic process is often
protracted, but even though the possibility of ALS may have been mentioned earlier, when the
diagnosis is confirmed, patients and family members are often shocked and overwhelmed.
After the diagnostic visit, patients (and accompanying family member) are commonly scheduled
to return to the clinic or office in 3 to 6 months. At this first routine clinic visit, the
focus is generally on assessment and management of mobility issues, diet, occupational
adjustments, advance planning directives, insurance coverage and other pressing issues that
usually take up the allotted time. Thus, there is often little opportunity to address the
emotional impact of the diagnosis at that visit.
Our goal is a manualized intervention suitable for telephone or Skype delivery, for the
management of distress and enhancement of coping skills among recently diagnosed ALS
patients and/or their family care partner. We are adapting the intervention developed by
Chesney, Folkman and colleagues, "Coping Effectiveness Training," as being the most salient
and theoretically powerful design for our purpose. We base our work on Folkman's revised
model that incorporates meaning-focused coping and the importance of positive emotions, in
addition to the original model of problem-focused and emotion-focused coping. The course of
ALS entails progressive losses, of mobility, fine and gross motor skills, speech,
swallowing, and respiration. Each requires recalibrating emotional response and coping with
new challenges. Early intervention to strengthen coping skills may equip patients and care
partners to handle new challenges as they arise, although in this initial study we will not
follow patients long enough to observe long-term effects, if present. Based on successful
findings in this pilot study, the next step will be to conduct a larger RCT of the
intervention.
Specific Aims and Hypotheses
AIM 1. To adapt and refine a manual for Coping Effectiveness Training for recently diagnosed
ALS patients and their care partners (CET-ALS) based on Coping Effectiveness Training (CET).
We will seek input from interviews with patients (whom we know from their participation in
our ongoing studies), care partners and ALS clinic staff.
AIM 2. Feasibility and Acceptability: Evaluate acceptability, attrition, participant
satisfaction and perceived barriers and facilitators to intervention delivery.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04948645 -
A Phase 1 Study to Investigate the Safety and Pharmacokinetics of ABBV-CLS-7262 in Patients With Amyotrophic Lateral Sclerosis
|
Phase 1 | |
Completed |
NCT02405182 -
MRI Biomarkers in ALS
|
||
Completed |
NCT00696332 -
Talampanel for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT03865420 -
Amyotrophic Lateral Sclerosis (ALS) Families Project
|
||
Terminated |
NCT04054141 -
rTMS in Treatment of Spasticity
|
N/A | |
Recruiting |
NCT03272503 -
A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Completed |
NCT05568615 -
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
|
Phase 3 | |
Recruiting |
NCT05635266 -
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
|
||
Active, not recruiting |
NCT04259255 -
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
|
||
Recruiting |
NCT02495571 -
Assessment of Voluntary and Reflex Cough in Patients With ALS
|
N/A | |
Completed |
NCT02525471 -
A Pilot Study of RNS60 in Amyotrophic Lateral Sclerosis (ALS)
|
Phase 1 | |
Recruiting |
NCT05031351 -
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
|
Phase 2 | |
Active, not recruiting |
NCT05581771 -
Factors Associated With Success of NIPPV in ALS Patients
|
||
Active, not recruiting |
NCT03268603 -
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
|
Phase 2 | |
Recruiting |
NCT05271435 -
Digital Tools for Assessment of Motor Functions and Falls in ALS
|
||
Completed |
NCT06005506 -
National Multicenter Interventional Study Aimed at Evaluating the Effect on the Intestinal Microbiota in Chronically Frail Patients Who Share Alterations in Intestinal Function.
|
N/A | |
Recruiting |
NCT04138095 -
Virtual Reality as an Adjunct to Management of Pain and Anxiety in Palliative Care
|
N/A | |
Recruiting |
NCT03698149 -
ECoG BMI for Motor and Speech Control
|
N/A | |
Not yet recruiting |
NCT05621213 -
Satisfaction of Patients With Amyotrophic Lateral Sclerosis Regarding Home Assisted Teleconsultation
|
N/A | |
Terminated |
NCT03373981 -
Non-invasive Brain Stimulation for the Treatment of Depression Symptoms in ALS
|
N/A |